Thông tin thuốc gốc
Chỉ định và Liều dùng
Monotherapy or adjunct in refractory partial seizures with or without secondary generalisation
Adult: In severe cases unresponsive to other drugs: As monotherapy: Initially, 1.2 g daily in 3 or 4 divided doses, may increase gradually by 0.6 g every 2 wk up to 2.4 g daily. May further increase if needed. Max: 3.6 g daily. As adjunctive treatment: Initially, 1.2 g daily in 3 or 4 divided doses, may increase by 1.2 g at wkly intervals up to 3.6 g daily. Reduce the dose of concomitant anticonvulsants by 20-33% when initiating felbamate therapy.
Child: As adjunct in Lennox-Gastaut syndrome: 2-<14 yr Initially, 15 mg/kg daily in 3 or 4 divided doses, may increase gradually in increments of 15 mg/kg at wkly intervals. Max: 45 mg/kg daily. Reduce the dose of concomitant anticonvulsants by 20% when initiating felbamate therapy; ≥14 yr Same as adult dose.
Renal Impairment
Reduce initial and maintenance doses by 50%.
Hepatic Impairment
Chống chỉ định
History of blood disorders. Active liver disease or history of hepatic impairment.
Thận trọng
Avoid abrupt withdrawal. Renal impairment. Childn. Pregnancy and lactation.
Phản ứng phụ
Nervous: Headache, dizziness, anorexia, insomnia, somnolence, anxiety.
GI: Nausea, vomiting, dyspepsia, constipation or diarrhoea.
Resp: Upper resp tract infection, rhinitis.
Hepatic: Increased SGPT.
Genitourinary: UTI, intramenstrual bleeding.
Ophthalmologic: Diplopia.
Otic: Otitis media.
Dermatologic: Photosensitivity, acne, rash, facial oedema.
Others: Fatigue, decreased wt, hypophosphataemia.
Potentially Fatal: Acute hepatic failure, aplastic anaemia.
Thông tin tư vấn bệnh nhân
Avoid exposure to UV radiation.
Perform CBC and LFT prior to and during treatment. Monitor for suicidality (e.g. depression, suicidal thoughts, mood/behavioural changes).
Tương tác
Enhanced metabolism w/ enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin). Prolonged half-life w/ gabapentin.
Tác dụng
Description: Felbamate is a carbamate w/ unknown mechanism of action, but has properties similar to other anticonvulsants. It has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex.
Absorption: Well absorbed from the GI tract. Bioavailability: ≥80%. Time to peak plasma concentration: 1-6 hr.
Distribution: Enters breast milk. Volume of distribution: 0.76 L/kg. Plasma protein binding: Approx 22-25%, mainly to albumin.
Metabolism: Partly metabolised in the liver via hydroxylation and conjugation to inactive metabolites.
Excretion: Mainly via urine (40-50% as unchanged drug, 40% as inactive metabolites); faeces (<5%). Terminal elimination half-life: 16-23 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Felbamate, CID=3331, https://pubchem.ncbi.nlm.nih.gov/compound/Felbamate (accessed on Jan. 20, 2020)

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Phân loại ATC
N03AX10 - felbamate ; Belongs to the class of other antiepileptics.
Anon. Felbamate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 20/02/2017.

Buckingham R (ed). Felbamate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/02/2017.

Felbamate Tablet (Amneal Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 20/02/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Felbamate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 20/02/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Felbamate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in